233 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
and the Plan of Arrangement. There can be no assurance that a Shareholder that dissents will receive consideration for his, her or its Shares of equal … be no assurance that a Shareholder that dissents will receive consideration for his, her or its Shares of equal or greater value to the Consideration
6-K
EX-99.3
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
reasonable assurance that
(i) material information relating to the issuer is made known to us by others, particularly during the period in which … legislation; and
(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability
6-K
EX-99.4
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
assurance that
(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings … ; and
(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
in NI 52-109) designed to provide reasonable assurance that information required to be disclosed by the Company in its annual filings, interim filings … reporting (as such term is defined in NI 52-109) designed to provide reasonable assurance regarding the reliability of financial reporting
6-K
EX-99.1
7qvl kox0yp3115va
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.1
qia a8xfvw8ermsj31d
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.3
qwlpfk ls
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.4
f3lzdomhj kygumiqzrt
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
zyzmoytzdxm028ykpjo
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
wdy88udu7kltd
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
n29dbiiwthqg mcuv4
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
uzq554e elx
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
e72sb8un23uezl0rd
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
18kg2bsr
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
7bor9lh818piy
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
sugeg8ina5 uao0
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
oxc7y1j4uyo 248
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.3
5xsyk w9gu
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.4
igtu1lno3gebn
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm